# NewAmsterdam Pharma clinical trials: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with NewAmsterdam Pharma as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by NewAmsterdam Pharma: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/newamsterdam-pharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 31, 2026 | NCT07794670 | Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease | NewAmsterdam Pharma | Phase 2 | Recruiting | Preclinical Alzheimer's Disease | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794670) |
| October 22, 2025 | NCT07219602 | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of... | NewAmsterdam Pharma | Phase 3 | Active not recruiting | Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07219602) |
| May 21, 2025 | NCT06982508 | Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | NewAmsterdam Pharma | Phase 2 | Recruiting | Antioxidant Absorption | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06982508) |
| August 9, 2024 | NCT06547359 | A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects | NewAmsterdam Pharma | Phase 1 | Completed | Healthy Volunteers | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06547359) |
| July 11, 2024 | NCT06496243 | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | NewAmsterdam Pharma | Phase 2 | Recruiting | Dyslipidemias | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06496243) |
| March 12, 2024 | NCT06305559 | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | NewAmsterdam Pharma | Phase 3 | Active not recruiting | Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06305559) |
| February 8, 2024 | NCT06250205 | Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib | NewAmsterdam Pharma | Phase 1 | Completed | Healthy Volunteers | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06250205) |
| October 13, 2023 | NCT06081166 | A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin | NewAmsterdam Pharma | Phase 1 | Completed | Healthy Volunteers | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06081166) |
| September 22, 2023 | NCT06050291 | Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe | NewAmsterdam Pharma | Phase 1 | Completed | Healthy Volunteer Study | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06050291) |
| September 21, 2023 | NCT06048302 | PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function | NewAmsterdam Pharma | Phase 1 | Completed | Hepatic Impairment, Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06048302) |
| August 22, 2023 | NCT06005597 | Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies | NewAmsterdam Pharma | Phase 3 | Completed | Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol | 407 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06005597) |
| August 2, 2023 | NCT05972278 | Investigating the Effect of Obicetrapib on Lipoprotein Metabolism | NewAmsterdam Pharma | Phase 1 | Unknown | Lipid Metabolism | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05972278) |
| June 21, 2022 | NCT05425745 | Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. | NewAmsterdam Pharma | Phase 3 | Completed | Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder... | 354 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05425745) |
| June 16, 2022 | NCT05421078 | A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. | NewAmsterdam Pharma | Phase 2 | Completed | Dyslipidemia, Hypercholesterolemia, High Cholesterol | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05421078) |
| March 4, 2022 | NCT05266586 | Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | NewAmsterdam Pharma | Phase 2 | Completed | Dyslipidemias, High Cholesterol, Hypercholesterolemia | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05266586) |
| January 21, 2022 | NCT05202509 | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | NewAmsterdam Pharma | Phase 3 | Active not recruiting | Atherosclerotic Cardiovascular Disease | 9,541 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05202509) |
| December 17, 2021 | NCT05161715 | Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease | NewAmsterdam Pharma | Phase 2 | Completed | Early Alzheimer's Disease | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05161715) |
| December 3, 2021 | NCT05142722 | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | NewAmsterdam Pharma | Phase 3 | Completed | Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular... | 2,530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05142722) |
| February 25, 2021 | NCT04770389 | Randomized Study of Obicetrapib in Combination With Ezetimibe | NewAmsterdam Pharma | Phase 2 | Completed | Dyslipidemias, High Cholesterol, Hypercholesterolemia | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04770389) |
| February 15, 2021 | NCT04753606 | Randomized Study of Obicetrapib as an Adjunct to Statin Therapy | NewAmsterdam Pharma | Phase 2 | Completed | Dyslipidemias, High Cholesterol, Hypercholesterolemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04753606) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 2 | 8 |
| Phase 3 | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Recruiting | 3 |
| Active not recruiting | 3 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dyslipidemias | 8 |
| Hypercholesterolemia | 7 |
| Atherosclerosis | 6 |
| Hyperlipoproteinemia Type II | 3 |
| Alzheimer Disease | 2 |
| Hyperlipidemias | 2 |
| Coronary Artery Disease | 1 |
| Plaque, Atherosclerotic | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Metabolic Syndrome | 1 |
| Lipid Metabolism Disorders | 1 |
| Metabolic Diseases | 1 |
| Lipid Metabolism, Inborn Errors | 1 |
| Genetic Diseases, Inborn | 1 |
| Hyperlipoproteinemias | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Avionics shops in the United States](https://specstream.ai/data/businesses/avionics-shops/united-states)
- [Internet marketing agencies in the United States](https://specstream.ai/data/businesses/internet-marketing-agencies/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [General hospitals in the United States](https://specstream.ai/data/businesses/general-hospitals/united-states)
- [Stone suppliers in the United States](https://specstream.ai/data/businesses/stone-suppliers/united-states)
- [Electronic equipment suppliers in the United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/united-states)
